204.28 USD
+3.61
1.8%
At close Updated Nov 14, 4:00 PM EST
Pre-market
After hours
203.01
-1.27
0.62%
1 day
1.8%
5 days
1.63%
1 month
18.21%
3 months
28.93%
6 months
34.98%
Year to date
27.2%
1 year
35.19%
5 years
149.61%
10 years
2,108.43%
 

About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Employees: 4,434

0
Funds holding %
of 7,520 funds
0
Analysts bullish %
of 9 analysts
0
Positive news %
of 12 articles
Price charts implemented using Lightweight Charts™